Alzheimer’s disease (AD) studies in cognitively normal (CN) older adults age≥65 suggest depression is associated with molecular biomarkers (imaging and cerebrospinal fluid [CSF]). This study used linear mixed models (covariance pattern model) to assess whether baseline CSF biomarkers (Aβ42/Aβ40, t-Tau/Aβ42, p-Tau/Aβ42) predicted changes in non-depressed mood states in CN older adults (N = 248), with an average of three follow-up years. Participants with higher levels of CSF biomarkers developed more anger, anxiety, and fatigue over time compared to those with more normal levels. Non-depressed mood states in preclinical AD may be a prodrome for neuropsychiatric symptoms in symptomatic AD.
LyketsosCG, SteeleC, BakerL, GalikE, KopunekS, SteinbergM, WarrenA (1997) Major and minor depression in Alzheimer’s disease: Prevalence and impact. J Neuropsychiatry Clin Neurosci9, 556–561.
IsmailZ, SmithEE, GedaY, SultzerD, BrodatyH, SmithG, Agüera-OrtizL, SweetR, MillerD, LyketsosCG (2016) Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement12, 195–202.
4.
GallagherD, KissA, LanctotK, HerrmannN (2018) Depression and risk of Alzheimer’s dementia: A longitudinal analysis to determine predictors of increased risk among older adults with depression. Am J Geriatr Psychiatry26, 819–827.
5.
Singh-ManouxA, DugravotA, FournierA, AbellJ, EbmeierK, KivimäkiM, SabiaS (2017) Trajectories of depressive symptoms before diagnosis of dementia: A 28-year follow-up study. JAMA Psychiatry74, 712–718.
MastersMC, MorrisJC, RoeCM (2015) “Noncognitive” symptoms of early Alzheimer disease A longitudinal analysis. Neurology84, 617–622.
8.
CreeseB, GriffithsA, BrookerH, CorbettA, AarslandD, BallardC, IsmailZ (2020) Profile of mild behavioral impairment and factor structure of the mild behavioral impairment checklist in cognitively normal older adults. Int Psychogeriatr32, 705–717.
9.
BabulalGM, GhoshalN, HeadD, VernonEK, HoltzmanDM, BenzingerTLS, FaganAM, MorrisJC, RoeCM (2016) Mood changes in cognitively normal older adults are linked to Alzheimer disease biomarker levels. Am J Geriatr Psychiatry24, 1095–1104.
10.
DonovanNJ, HsuDC, DagleyAS, SchultzAP, AmariglioRE, MorminoEC, OkerekeOI, RentzDM, JohnsonKA, SperlingRA, MarshallGA (2015) Depressive symptoms and biomarkers of Alzheimer’s disease in cognitively normal older adults. J Alzheimers Dis46, 63–73.
11.
DonovanNJ, LocascioJJ, MarshallGA, GatchelJ, HanseeuwBJ, RentzDM, JohnsonKA, SperlingRA, Harvard Aging Brain S (2018) Longitudinal association of amyloid beta and anxious-depressive symptoms in cognitively normal older adults. Am J Psychiatry175, 530–537.
12.
GatchelJR, RabinJS, BuckleyRF, LocascioJJ, QuirozYT, YangH-S, VanniniP, AmariglioRE, RentzDM, ProperziM (2019) Longitudinal association of depression symptoms with cognition and cortical amyloid among community-dwelling older adults. JAMA Network Open2, e198964.
13.
BabulalGM, RoeCM, StoutSH, RajasekarG, WischJK, BenzingerTLS, MorrisJC, AncesBM (2020) Depression is associated with tau and not amyloid positron emission tomography in cognitively normal adults. J Alzheimers Dis74, 1045–1055.
14.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
15.
FaganAM, MintunMA, MachRH, LeeSY, DenceCS, ShahAR, LaRossaGN, SpinnerML, KlunkWE, MathisCA (2006) Inverse relation between amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol59, 512–519.
FaganAM, MintunMM, ShahAR, AldeaP, RoeCM, MachRH, MarcusD, MorrisJC, HoltzmanDM (2009) Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med1, 371–380.
19.
FaganAM, RoeCM, XiongC, MintunMA, MorrisJC, HoltzmanDM (2007) Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol64, 343–349.
20.
FaganAM, YounkinLH, MorrisJC, FryerJD, ColeTG, YounkinSG, HoltzmanDM (2000) Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol48, 201–210.
21.
VolluzKE, SchindlerSE, HensonRL, XiongC, GordonBA, BenzingerTLS, HoltzmanDM, MorrisJC, FaganAM (2021) Correspondence of CSF biomarkers measured by Lumipulse assays with amyloid PET. Alzheimers Dement17, e051085.
22.
CurranSL, AndrykowskiMA, StudtsJL (1995) Short form of the Profile of Mood States (POMS-SF): Psychometric information. Psychol Assess7, 80.
23.
CooperJK, MungasD, WeilerPG (1990) Relation of cognitive status and abnormal behaviors in Alzheimer’s disease. J Am Geriatr Soc38, 867–870.
24.
RuthirakuhanM, LanctôtKL, Di ScipioM, AhmedM, HerrmannN (2018) Biomarkers of agitation and aggression in Alzheimer’sdisease: A systematic review. Alzheimers Dement14, 1344–1376.
25.
DevierDJ, PeltonGH, TabertMH, LiuX, CuasayK, EisenstadtR, MarderK, SternY, DevanandDP (2009) The impact of anxiety on conversion from mild cognitive impairment to Alzheimer’s disease. Int J Geriatr Psychiatry24, 1335–1342.
26.
RamakersI, VisserPJ, AaltenP, KesterA, JollesJ, VerheyFRJ (2010) Affective symptoms as predictors of Alzheimer’s disease in subjects with mild cognitive impairment: A 10-year follow-up study. Psychol Med40, 1193–1201.
27.
GulpersB, RamakersI, HamelR, KöhlerS, VoshaarRO, VerheyF (2016) Anxiety as a predictor for cognitive decline and dementia: A systematic review and meta-analysis. Am J Geriatr Psychiatry24, 823–842.
28.
MahL, BinnsMA, SteffensDC, Alzheimer’s Disease Neuroimaging Initiative (2015) Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. Am J Geriatr Psychiatry23, 466–476.
29.
AvlundK (2010) Fatigue in older adults: An early indicator of the aging process? . Aging Clin Exp Res22, 100–115.
30.
MortbyME, IsmailZ, AnsteyKJ (2018) Prevalence estimates of mild behavioral impairment in a population-based sample of pre-dementia states and cognitively healthy older adults. Int Psychogeriatr30, 221–232.
31.
CreeseB, BrookerH, IsmailZ, WesnesKA, HampshireA, KhanZ, MegalogeniM, CorbettA, AarslandD, BallardC (2019) Mild behavioral impairment as a marker of cognitive decline in cognitively normal older adults. Am J Geriatr Psychiatry27, 823–834.
32.
LussierFZ, PascoalTA, ChamounM, TherriaultJ, TissotC, SavardM, KangMS, MathotaarachchiS, BenedetAL, ParsonsM (2020) Mildbehavioral impairment is associated with β-amyloid but nottau or neurodegeneration in cognitively intact elderly individuals. Alzheimers Dement16, 192–199.
33.
NaudeJP, GillS, HuS, McGirrA, ForkertND, MonchiO, StysPK, SmithEE, IsmailZ, Alzheimer’s Disease Neuroimaging Imaging (2020) Plasmaneurofilament light: A marker of neurodegeneration in mildbehavioral impairment. J Alzheimers Dis76, 1017–1027.
34.
OpdebeeckC, MatthewsFE, WuY-T, WoodsRT, BrayneC, ClareL (2018) Cognitive reserve as a moderator of the negative association between mood and cognition: Evidence from a population-representative cohort. Psychol Med48, 61–71.
